Immatics
gen preclinical assessment of anti tumor efficacy me | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
27 of 75
Related slides by other companies
Matinas BioPharma
Investor Presentation
January 2024
in tumor cell inhibition with formulations rationale and next steps | Matinas BioPharma
Matinas BioPharma
Investor Presentation
November 2023
in dose dependent knockdown of a in murine cells | Matinas BioPharma
Matinas BioPharma
Investor Presentation
November 2023
in tumor cell inhibition with formulations | Matinas BioPharma
Matinas BioPharma
Investor Presentation
February 2024
in tumor cell inhibition with formulations rationale and next steps | Matinas BioPharma
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights